318.7
1 There is no dilution effect for potential ordinary shares for periods where earnings have been negative.
2 Alternative performance measure (APM). Defined on page 20 in the interim report.
CEO Comments
The first quarter of 2021 has been very productive for Vicore continuing to build on the clinical success achieved with C21 in 2020.
In the beginning of February, the company raised 336 MSEK (approx. 40 MUSD) in a directed share issue that attracted Swedish and international institutional investors, including existing shareholders. The strengthened financial position allows Vicore to fund operations well into 2023.
The fundraising followed results of Vicore s phase II COVID-19 trial ATTRACT. The data, published on the online preprint server medRxiv at the beginning of January, showed that C21, Vicore s angiotensin type 2 receptor agonist, spares the need for oxygen supplementation and clearly restores respiratory function in hospitalized COVID-19 patients. Following the
Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF
- Webinar will be held today at 15:00 CET (9:00 am EST)
- Digital therapeutics expert Jessica Shull joins Vicore to drive DTx program
News provided by
Share this article
GOTHENBURG, Sweden, May 4, 2021 /PRNewswire/
Vicore Pharma Holding AB (publ) ( Vicore ), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the signing of an agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx Platform . Vicore will hold a webinar at 15:00 CET (9 AM EST) today to outline the strategic importance and operational details of the new program.
Share this article
GOTHENBURG, Sweden, April 20, 2021 /PRNewswire/
Vicore Pharma Holding AB (publ) ( Vicore ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announced that it will host a key opinion leader (KOL) webinar on C21, the company s lead asset for the treatment of COVID-19, on Wednesday, April 28, 2021 at 14:00 CET (8 am EST).
The event will feature a presentation by KOL Professor Maureen Horton, M.D., Johns Hopkins University School of Medicine, who will discuss the current treatment landscape and unmet medical needs in treating patients with COVID-19. Professor Horton will be available to answer questions following the conclusion of the event.
Vicore Pharma s drug candidate C21 dilates peripheral resistance vessels in fibrotic disease
News provided by
Share this article
GOTHENBURG, Sweden, March 11, 2021 /PRNewswire/
Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces top line data from a phase II study of its oral angiotensin II type 2 receptor (AT2R) agonist C21 in patients with systemic sclerosis and Raynaud s phenomenon. In this mechanistic 12-person single-dose study, C21 did not reach the predefined area-under-curve endpoint but at the end of the measurement C21 treatment showed statistically significant evidence of restored skin temperature as a measure of dilated peripheral resistance vessels.
Share this article
GOTHENBURG, Sweden, Feb. 1, 2021 /PRNewswire/
Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today published data from the phase II study ATTRACT online and submitted it to a peer reviewed journal. The results show restoration of lung function in COVID-19 on top of corticosteroids and remdesivir with the company s oral drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic.
With close to 100 million registered cases and 2 million deaths to date, there is an urgent need for a safe oral effective therapy to complement the recently launched vaccines. Vicore Pharma s angiotensin II type 2 receptor (AT2R) agonist C21 showed restoration of respiratory function with a significantly lower risk of being on supplemental oxygen at the end of treatment and during follow up.